XML 31 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

Common Stock Options | 12 Months Ended
--- | ---
Dec. 31, 2020
Common Stock Options [Abstract] |
Common Stock Options | Note 9. Common Stock Options Stock options The 1997 Stock Option Plan (the “1997 Plan”) and 2013 Equity Incentive Plan (the “2013 Plan”) authorize the issuance of both nonqualified and incentive stock options. Payment for the shares may be made in cash, shares of the Company’s common stock or a combination thereof. Under the terms of the plans, incentive stock options and non-qualified stock options are granted at a minimum of 100% of fair market value on the date of grant and may be exercised at various times depending upon the terms of the option. All existing options expire 10 years from the date of grant or one year from the date of death. Stock-based compensation Under the 2013 Plan, the Company is authorized to grant options to purchase up to 600,000 shares of its common stock. As of December 31, 2020, options to purchase an aggregate of 325,000 shares were outstanding under the 2013 Plan, of which options to purchase 315,000 shares were exercisable, and 275,000 additional shares were available for issuance pursuant to awards that may be granted under the plan in the future. Under the 1997 Plan, the Company was authorized to grant options to purchase up to 450,000 shares of its common stock. As of December 31, 2020, options to purchase an aggregate of 7,500 shares were outstanding and exercisable under the 1997 Plan. The board terminated the plan in 2014. The existing grants may be exercised according to the terms of the grant agreements. There were no options granted during the years ended December 31, 2020 and 2019. The following table summarizes the activity for outstanding incentive stock options under the 2013 Plan to employees of the company:
|  |  | Options Outstanding |
|  |  | Number of Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (1) |
Balance at January 1, 2019 |  |  |  | 125,000 |  |  | $ | 3.78 |  |  |  | 8.1 |  |  |  |  |
Granted |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Canceled/forfeited/expired |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Balance at December 31, 2019 |  |  |  | 125,000 |  |  |  | 3.78 |  |  |  | 7.1 |  |  |  |  |
Granted |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Canceled/forfeited/expired |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
B alance at December 31, 2020 |  |  |  | 125,000 |  |  | $ | 3.78 |  |  |  | 6.1 |  |  |  |  |
Vested and exercisable as of December 31, 2020 |  |  |  | 115,000 |  |  |  |  |  |  |  |  |  |  | $ | 118 |
| (1) | The aggregate intrinsic value is calculated as approximately the difference between the weighted average exercise price of the underlying awards and the Company’s estimated current fair market value at December 31, 2020.
The following table summarizes the activity for outstanding stock options under the 2013 Plan and 1997 Plan to directors of the company:
|  |  | Options Outstanding |
|  |  | Number of Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (1) |
Balance at January 1, 2019 |  |  |  | 207,500 |  |  | $ | 4.62 |  |  |  | 4.4 |  |  |  |  |
Granted |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Canceled/forfeited/expired |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Balance at December 31, 2019 |  |  |  | 207,500 |  |  |  | 4.62 |  |  |  | 3.4 |  |  |  |  |
Granted |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Canceled/forfeited/expired |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Balance at December 31, 2020 |  |  |  | 207,500 |  |  | $ | 4.62 |  |  |  | 2.4 |  |  |  |  |
Vested and exercisable as of December 31, 2020 |  |  |  | 207,500 |  |  |  |  |  |  |  |  |  |  | $ | 40 |
| (1) | The aggregate intrinsic value is calculated as approximately the difference between the weighted average exercise price of the underlying awards and the Company’s estimated current fair market value at December 31, 2020.
The Company recognized compensation expense in connection with the issuance of the options of approximately $6 and $11 during the years ended December 31, 2020 and 2019, respectively. There were no options exercised during the years ended December 31, 2020 and 2019. As of December 31, 2020, there was approximately $9 of unrecognized compensation expense under the 2013 Plan. The Company expects to recognize this expense over the next two years. To the extent the forfeiture rate is different than we have anticipated, stock-based compensation related to these awards will be different from our expectations.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration